Medtronic plc (NYSE:MDT) reported fiscal third-quarter 2026 results that exceeded analyst expectations, posting revenue of $9.0 billion. Sales rose 8.7% on a reported basis and 6.0% organically compared with the same period a year earlier.
Adjusted earnings per share came in at $1.36, ahead of the $1.34 consensus estimate, while revenue also surpassed forecasts of $8.89 billion. The company noted that the quarter delivered its highest enterprise revenue growth in the past 10 quarters. Shares slipped 0.5% following the announcement.
The Cardiovascular Portfolio led performance, with revenue climbing 13.8% as reported and 10.6% organically to $3.46 billion. Within that segment, Cardiac Ablation Solutions stood out, recording 80% global growth and a 137% increase in the U.S., supported by strong uptake of its pulsed field ablation products.
“Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio,” said Geoff Martha, Medtronic chairman and chief executive officer. “By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company.”
Elsewhere, the Neuroscience Portfolio rose 4.1% as reported to $2.56 billion, the Medical Surgical Portfolio advanced 4.9% to $2.17 billion, and the Diabetes segment grew 14.8% to $796 million.
Medtronic reaffirmed its fiscal 2026 outlook, maintaining expectations for approximately 5.5% organic revenue growth and adjusted EPS between $5.62 and $5.66. The guidance factors in a potential $185 million impact from tariffs.